Contrasting Peak Pharmaceuticals (OTCMKTS:PKPH) and Innovus Pharmaceuticals (OTCMKTS:INNVD)

Profitability

This table compares Peak Pharmaceuticals and Innovus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Pharmaceuticals	N/A	N/A	-159.55%
Innovus Pharmaceuticals	-34.51%	-682.54%	-78.57%

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 18.4% of Peak Pharmaceuticals shares are owned by insiders. Comparatively, 16.4% of Innovus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Peak Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500.

Earnings and Valuation

This table compares Peak Pharmaceuticals and Innovus Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Pharmaceuticals	N/A	N/A	-$160,000.00	N/A	N/A
Innovus Pharmaceuticals	$23.99 million	0.00	-$8.28 million	($4.16)	N/A

Peak Pharmaceuticals has higher earnings, but lower revenue than Innovus Pharmaceuticals.

About Peak Pharmaceuticals

Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.